Novosti
Khirurgii

 This journal is
indexed in Scopus
journal cover
android icon Android Applicaion

Year 2014 Vol. 22 No 6

SCIENTIFIC PUBLICATIONS
EXPERIMENTAL SURGERY

V.À. KOSINETS

THE EFFECTS OF INTERLEUKIN-2 ON THE SMALL INTESTINE STRUCTURAL STATE IN EXPERIMENTAL GENERALIZED PURULENT PERITONITIS

EE “Vitebsk State Medical University”
The Republic of Belarus

Objectives. To study the effects of recombinant interleukin-2 on structural changes in the small intestine wall in experimental generalized purulent peritonitis.
Methods. The experiment was carried out on 40 male rabbits divided into the following groups: intact (n=5); 6-hour peritonitis without surgical treatment (n=5); control (n=15) – surgical treatment of peritonitis; main (n=15) – surgical treatment of peritonitis with the use of the recombinant interleukin-2 – roncoleukin for postoperative peritonitis. In the postoperative period the main group of animals intravenously injected roncoleukin in a dose of 10 000 IU/kg twice daily within 5-days. Tissue samples of the small intestine were morphologically examined by light microscopy.
Results. The expressed inflammatory and destructive changes in the small intestine wall in 6 hours after induction of peritonitis have been revealed. Disturbances of blood and lymph circulation, destruction of villi of mucous coat, dystrophic and necrotic changes in muscular coat testified to the early terms of enteral insufficiency development in generalized purulent peritonitis. In the postoperative period after laparotomy, sanitation of the abdominal cavity and decompression of the small intestine the morphological picture of pathological disturbances of the structure of the small intestine coats had no accurate tendency to improvement.
Conclusion. Development of experimental generalized purulent peritonitis is accompanied by the expressed early changes of the structure of the small intestine wall leading to the colonization resistance disturbance caused the intestinal paresis and its transformation to the infection reservoir.
Traditional surgery doesn't stop the progressing of the pathological process in the small intestine continuing to expand in the postoperative period.
In case of peritonitis intravenous administration of recombinant interleukin-2 has direct effects on the inflammatory process course in the small intestine and prevents the development of destructive processes in its tissues. The data obtained allow considering this property when administering the drug in treatment of generalized purulent peritonitis.

Keywords: generalized purulent peritonitis, small intestine, structural changes, inflammation, immune system, interleukin-2, roncoleukin
p. 643-648 of the original issue
References
  1. Gostishchev VK, Sazhin VP, Avdovenko AL. Peritonit [Peritonitis]. Moscow, RF: GEOTAR-Media; 2002. 238 p.
  2. Savel'ev VS, Gel'fand BR, Filimonov MI. Peritonit [Peritonitis]. Prakticheskoe rukovodstvo. Moscow, RF: Litterra; 2006. 208 p.
  3. Grishina TI. Klinicheskoe znachenie narusheniia immuniteta pri khirurgicheskikh vmeshatel'stvakh [The clinical significance of impaired immunity in surgical interventions]. Andrologiia i genital'naia khirurgiia. 2000;(2):35–38.
  4. Efimenko NA, Rozanov VE, Bolotnikov AI. Immunopatogenez i kontseptsiia sovremennoi immunoterapii peritonita u postradavshikh s tiazheloi sochetannoi travmoi zhivota [Immunopathogenesis and modern concept of immunotherapy of peritonitis in patients with severe combined trauma of the abdomen]. Moscow. RF: OOO Avtograf, 2008. 302 p.
  5. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy. 2005;51 Suppl 1:1–22.
  6. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC, Bozza PT. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care. 2007;11(2):R49.
  7. Fjell CD, Thair S, Hsu JL, Walley KR, Russell JA, Boyd J. Cytokines and signaling molecules predict clinical outcomes in sepsis. PLoS One. 2013 Nov 14;8(11):e79207
  8. Oberholzer A, Souza SM, Tschoeke SK, Oberholzer C, Abouhamze A, Pribble JP, Moldawer LL. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock. 2005 Jun;23(6):488–93.
  9. Wilson PG, Manji M, Neoptolemos JP. Acute pancreatitis as a model of sepsis. J Antimicrob Chemother. 1998 Jan;41 Suppl A:51–63.
  10. Bubnova NA. Egorova VN. Obobshchennyi opyt primeneniia Ronkoleikina (rekombinantnogo interleikina-2) v lechenii khirurgicheskikh zabolevanii [Generalized experience of Roncoleukin (recombinant interleukin-2) in the treatment of surgical diseases]: posobie dlia vrachei. Saint-Petersburg, RF: Al'ter Ego, 2010. 80 p.
  11. Egorova VN, Popovich AM. Ronkoleikin®.Opyt primeneniia v khirurgii i reanimatologii [Ronkoleykin®. Experience in surgery and resuscitation]. Saint-Petersburg, RF: Al'ternativnaia Poligrafiia, 2004. 48 p.
  12. Kozlov VK. Disfunktsiia immunnoi sistemy v patogeneze sepsisa: vozmozhnosti diagnostiki [Immune system dysfunction in sepsis: diagnostic potential. Cytokines and inflammation]. Tsitokiny i Vospalenie. 2006;5(2):15–29.
  13. Kozlov VK. Immunopatogenez i tsitokinoterapiia khirurgicheskogo sepsisa [Immunopathogenesis and cytokine therapy of surgical sepsis]. Vestn Ross Voen Med Akademii. 2002;2(8):12–22.
  14. Kozlov VK. Sepsis: etiologiia, immunopatogenez, kontseptsiia sovremennoi immunoterapii [Sepsis: etiology, immunopathogenesis, and concept of modern immunotherapy]. Saint-Petersburg, RF: Dialekt; 2006. 304 p.
  15. Kosmaczewska A.Low-Dose Interleukin-2 Therapy: A Driver of an Imbalance between Immune Tolerance and Autoimmunity. Int J Mol Sci. 2014 Oct 15;15(10):18574–92.
  16. Hoyer KK, Dooms H, Barron L, Abbas AK. Interleukin-2 in the development and control of inflammatory disease. Immunol Rev. 2008 Dec;226:19–28
  17. Miae Jeon, Hyun Jung Kwon, Yong Hyun Kim, Kook-Il Han, Kung-Woo Nam, Yeongjun Baik, Sunghee Lee, Wan-Jong Kim, Man-Deuk Han. Pretreatment with recombinant human interleukin 2 (rhIL-2) Up-regulates PCNA-positive cells after partial hepatectomy in rat liver. Biotechnology and Bioprocess Engineering. Feb 2014;19(1):43–51.
Address for correspondence:
210023, Respublika Belarus, g. Vitebsk, pr-t Frunze, d. 27,
UO «Vitebskiy gosudarstvennyiy
meditsinskiy universitet», kafedra gospitalnoy khirurgii
s kursami urologii i detskoy khirurgii,
tel. mob.: 375 296 24 20 76,
e-mail: vkosinets@yandex.ru,
Kosinets Vladimir Aleksandrovich
Information about the authors:
Kosinets V.A. MD, professor of the hospital surgery chair with courses of urology and pediatric surgery of EE “Vitebsk State Medical University”.
Contacts | ©Vitebsk State Medical University, 2007-2023